NSCLC

[Journal of Experimental & Clinical Cancer Research] The Jurkat T cells and non-small cell lung cancer cells co-culture model was used to assess the effect of apatinib on T cells activation. Subcutaneous tumor formation models were established to evaluate the effects of apatinib in vivo.

[Cell Death & Disease] Researchers investigated the combined influence of cancer stem cells (CSCs), circRNA, and immune checkpoint inhibitors in NSCLC progression and therapy resistance. They constructed lung CSCs.

[Cancer Gene Therapy] Researchers demonstrated that F-BAR and mu homology domains existed separately in human lung tissues and that one truncated form was not detected in patients with lung cancer.

[Riken Genesis Co., Ltd. (GlobeNewsWire, Inc.)] Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. announced that the Ministry of Health, Labour and Welfare has approved the AmoyDx® Pan Lung Cancer PCR Panel as a companion diagnostic for TEPMETKO® a Merck KGaA, Darmstadt, Germany product that received approval by the Japanese MHLW in March 2020.

[Galecto, Inc.] Galecto, Inc. announced the treatment of the first patient in a Phase IIa trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. The current standard of care for myelofibrosis is JAK inhibitors, but questions remain regarding side effects caused by the mechanism of action.

[Nature Medicine] Scientists discuss some of the recent breakthrough therapies developed for NSCLC, focusing on immunotherapies and targeted therapies.